A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration； the uses of such combination in the treatment of proliferative diseases； and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
